Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study

Dow Jones05-27

By Christopher Kuo

Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients.

The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date.

The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors.

The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients.

Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 26, 2026 14:59 ET (18:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638542183?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638542183","market":"other","top_or_hot":-1,"title":"Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients. \n</p>\n<p>\n  The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date. \n</p>\n<p>\n  The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors. \n</p>\n<p>\n  The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients. \n</p>\n<p>\n  Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 26, 2026 14:59 ET (18:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-27 02:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients. \n</p>\n<p>\n  The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date. \n</p>\n<p>\n  The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors. \n</p>\n<p>\n  The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients. \n</p>\n<p>\n  Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 26, 2026 14:59 ET (18:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2638542183","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638542183","pubTimestamp":1779821940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients.The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date.The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors.The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients.Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRBP":"Corbus Pharmaceuticals Holdings, Inc."},"translate_title":"Corbus Pharmaceuticals因肿瘤治疗研究中的不良事件报告而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBP":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients. \n\n\n  The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date. \n\n\n  The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors. \n\n\n  The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients. \n\n\n  Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 14:59 ET (18:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638542183","isCrawlerRequest":true}